John Matthew Ringman
Affiliation: University of California
- Children of persons with Alzheimer disease: what does the future hold?Lissy Jarvik
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA 90095, USA
Alzheimer Dis Assoc Disord 22:6-20. 2008..We examine the state of knowledge with respect to risk and protective factors for AD and recommend a research agenda with special emphasis on AD offspring...
- New genes and new insights from old genes: update on Alzheimer diseaseJohn M Ringman
Easton Center for Alzheimer s Disease Research at UCLA, 10911 Weyburn Ave, 200, Los Angeles, CA 90095 7226, USA
Continuum (Minneap Minn) 19:358-71. 2013..This article discusses the current status of knowledge regarding the genetic basis of Alzheimer disease (AD) with a focus on clinically relevant aspects...
- Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotypeJohn M Ringman
Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095, USA
Arch Neurol 69:757-64. 2012..To study the effect of familial Alzheimer disease (FAD) mutations and APOE genotype on plasma signaling protein levels...
- Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's diseaseRandall J Bateman
Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
Alzheimers Res Ther 3:1. 2011..Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention...
- The Huntington disease of woody guthrie: another man done goneJohn M Ringman
UCLA Department of Neurology, Los Angeles, CA
Cogn Behav Neurol 20:238-43. 2007..Woody's most productive time artistically was in the 5 years immediately preceding the onset of overt symptoms of HD. I hypothesize that subclinical HD may have been an important driving force behind Woody Guthrie's creativity...
- Mosaicism for trisomy 21 in a patient with young-onset dementia: a case report and brief literature reviewJohn M Ringman
Alzheimer s Disease Research Center, Department of Neurology, University of California, Los Angeles, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095 7226, USA
Arch Neurol 65:412-5. 2008..To describe a case of young-onset Alzheimer disease (AD) due to mosaicism for trisomy 21...
- Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriersJohn M Ringman
Alzheimer s Disease Research Center, UCLA, Los Angeles, CA 90095 7226, USA
Dement Geriatr Cogn Disord 25:380-4. 2008..In our study we compared the prevalence of headaches between nondemented FAD mutation carriers (MCs) and non-mutation-carrying controls (NCs)...
- Myopathy associated with chronic orlistat consumption: a case reportJohn M Ringman
Alzheimer Disease Research Center, UCLA Department of Neurology, 10911 Weyburn Avenue, Suite 200, Los Angeles, CA 90095 7226, USA
Neuromuscul Disord 18:410-2. 2008..Orlistat may have caused this myopathy through depletion of a critical nutrient or through some as of yet undefined mechanism...
- Biochemical markers in persons with preclinical familial Alzheimer diseaseJ M Ringman
UCLA Department of Neurology, Alzheimer Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
Neurology 71:85-92. 2008..Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease...
- Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's diseaseJohn M Ringman
Mary S Easton Center for Alzheimer s Disease Research at UCLA, Associate Clinical Professor, UCLA Department of Neurology, 10911 Weyburn Ave, 200, Los Angeles, CA 90095 7226, USA
Curr Alzheimer Res 6:341-6. 2009..The study of FAD provides an opportunity to test various criteria for early AD and these observations should be taken into consideration in future iterations of such diagnostic criteria...
- Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer's diseaseJohn Matthew Ringman
UCLA Department of Neurology, Mary S Easton Center for Alzheimer s Disease Research, UCLA, 10911 Weyburn Ave, 200 Los Angeles, CA 90095 7226, USA
J Neurol 257:839-42. 2010..Our results suggest that radiologists' ability to detect HA in persons in whom the diagnosis of incipient AD is certain is sub-optimal and quantitative MRI techniques or other biological markers of the disease are needed...
- Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding taskJohn M Ringman
Mary S Easton Center for Alzheimer s Disease Research, Department of Neurology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90095, USA
Cereb Cortex 21:877-83. 2011..Our findings of increased fMRI activation associated with APOE genotype but not with FAD mutations suggest that APOE exerts an effect on the BOLD signal that is not readily explained as a compensatory phenomenon...
- The use of profanity during letter fluency tasks in frontotemporal dementia and Alzheimer diseaseJohn M Ringman
UCLA Department of Neurology, Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
Cogn Behav Neurol 23:159-64. 2010..To assess whether the production of profanity during letter fluency testing distinguishes frontotemporal dementia (FTD) and Alzheimer disease (AD) patients...
- Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutationJohn M Ringman
Mary S Easton Center for Alzheimer s Disease Research, UCLA Department of Neurology, Los Angeles, CA, United States
Neurosci Lett 487:287-92. 2011..We describe biochemical, imaging, and neuropathological changes in a pedigree with a novel PSEN1 mutation. This allows us to validate the pathogenicity of this mutation and the indices used to assess AD...
- Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutationsJohn M Ringman
Mary S Easton Center for Alzheimer s Disease Research, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095, USA
Arch Neurol 69:96-104. 2012..To identify cerebrospinal fluid (CSF) protein changes in persons who will develop familial Alzheimer disease (FAD) due to PSEN1 and APP mutations, using unbiased proteomics...
- Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutationsJohn M Ringman
UCLA Department of Neurology, Alzheimer s Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
Brain 130:1767-76. 2007..Decreased FA in of the columns of the fornix is particularly robust in early FAD and may provide a biomarker for early disease in sporadic Alzheimer's disease...
- Hemispheric asymmetry of gaze deviation and relationship to neglect in acute strokeJ M Ringman
Department of Neurology, University of California, Los Angeles, CA 90095 1769, USA
Neurology 65:1661-2. 2005..There was no difference in its rate of co-occurrence with neglect between right- and nonright-handed patients...
- What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a reviewJohn M Ringman
UCLA Alzheimer Disease Center, Los Angeles, CA 90095 1769, USA
J Geriatr Psychiatry Neurol 18:228-33. 2005..Studies of biochemical markers suggest that elevations of plasma A 1-42 occur early in familial Alzheimer's disease but that tau may not be elevated in cerebrospinal fluid until the disease is more advanced...
- Neuropsychological function in nondemented carriers of presenilin-1 mutationsJ M Ringman
Alzheimer s Disease Center, University of California, Los Angeles, CA 90095 1769, USA
Neurology 65:552-8. 2005..Prospective and case-control studies have demonstrated that memory loss and executive dysfunction occur early in Alzheimer disease (AD)...
- Current and emerging pharmacological treatment options for dementiaJohn M Ringman
Department of Neurology, Alzheimer s Disease Research Center, University of California, Los Angeles, CA 90095 1769, USA
Behav Neurol 17:5-16. 2006..Their clinical utility is controversial. Many novel approaches that promise to provide more effective treatments are currently being pursued...
- A potential role of the curry spice curcumin in Alzheimer's diseaseJohn M Ringman
University of California, Los Angeles, Department of Neurology, Alzheimer s Disease Research Center, Los Angeles, CA 90095, USA
Curr Alzheimer Res 2:131-6. 2005..We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology...
- Performance on MMSE sub-items and education level in presenilin-1 mutation carriers without dementiaJohn M Ringman
Alzheimer s Disease Center, UCLA Department of Neurology, Los Angeles, CA, USA
Int Psychogeriatr 19:323-32. 2007..Persons known to be at 50% risk for young-onset AD due to presenilin-1 (PSEN1) mutations provide the opportunity to assess which measures on the Mini-mental State Examination (MMSE) are most sensitive to these early changes...
- Frequency, risk factors, anatomy, and course of unilateral neglect in an acute stroke cohortJ M Ringman
Department of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Suite 2 238, Los Angeles, CA 90095 1769, USA
Neurology 63:468-74. 2004..To delineate the frequency, course, risk factors, and neuroanatomy of hemispatial neglect in a large stroke cohort...
- Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression than their non-mutation carrying kinJ M Ringman
Alzheimer s Disease Center, UCLA Department of Neurology, Los Angeles, California 90095 1769, USA
J Neurol Neurosurg Psychiatry 75:500-2. 2004..To study depressive symptoms in preclinical presenilin-1 (PS1) related Alzheimer's disease...
- An African American family with early-onset Alzheimer disease and an APP (T714I) mutationT Edwards-Lee
Department of Neurology, Harbor UCLA Medical Center, Torrance, USA
Neurology 64:377-9. 2005..Distinct from that family, seizures and myoclonus were prominent features of the disease in this kindred...
- Carbonic anhydrase inhibitors and amobarbital resistanceJohn M Ringman
Epilepsia 46:1333. 2005
- Earlier Alzheimer onset in Latino persons: ethnic difference vs selection biasJohn M Ringman
Arch Neurol 62:1786-7. 2005
- Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteriaEdmond Teng
Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
Am J Geriatr Psychiatry 16:469-77. 2008....
- The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen familiesJill Murrell
Department of Pathology and Laboratory Medicine, University of Indiana Medical School, 635 Barnhill Drive, MS A128, Indianapolis, IN 46202 5126, USA
Neurogenetics 7:277-9. 2006....
- The Thr354Ile substitution in PSEN1:: disease-causing mutation or polymorphism?Peiyee Lee
Department of Neurology, University of California Los Angeles, 90095 1769, USA
Neurology 66:1955-6. 2006
- Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcuminMilan Fiala
Department of Medicine, Greater Los Angeles Veterans Affairs Medical Center, and School of Medicine, University of California Los Angeles, CA 90095, USA
Proc Natl Acad Sci U S A 104:12849-54. 2007..Thus, bisdemethoxycurcumin may correct immune defects of AD patients and provide a previously uncharacterized approach to AD immunotherapy...
- An experimental approach to detecting dementia in Down syndrome: a paradigm for Alzheimer's diseaseLinda D Nelson
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, C8 749, Semel Institute, 760 Westwood Plaza, Los Angeles, CA 90095 1759, USA
Brain Cogn 64:92-103. 2007..Results demonstrated high validity and reliability of select tests. The implication of early symptom detection in a population at-risk for AD-type dementia was discussed in terms of potential brain regions of interest...
- Visualizing language deterioration in progressive aphasiasJohn M Ringman
Neurology 67:1738-9. 2006
- The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in MexicoJohn M Ringman
Department of Neurology, UC Irvine School of Medicine, Irvine, California, USA
Neuropsychiatry Neuropsychol Behav Neurol 15:99-105. 2002..To study the incidence of behavioral abnormalities in patients with Parkinson's disease (PD) and extend them to a Mexican population...
- Mitochondrial encephalomyopathy with lactic acidosis and stroke (MELAS)Joyce Matsumoto
Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Rev Neurol Dis 2:30-4. 2005..In this case review we briefly discuss the signs and symptoms, frequency, pathophysiology, and prognosis of this disorder...
- Spasmodic dysphonia in a patient with the A to G transition at nucleotide 8344 in mitochondrial DNAYing Peng
Department of Pediatrics, University of California at Irvine, Orange, California 92868, USA
Mov Disord 18:716-8. 2003..This patient also had spasmodic dysphonia that was responsive to treatment with intralaryngeal botulinum toxin...
- FMRI in Pre-Symptomatic PS1-related Alzheimer's DiseaseJohn Ringman; Fiscal Year: 2005..UCI, with its strong dementia research program, growing MRI capabilities and opportunity to collaborate at the nearby UCLA Brain Imaging Center, is an excellent environment for this endeavor. ..